Shockwave Medical Inc
F:36M
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (16.2), the stock would be worth €282.67 (8% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 17.6 | €307.7 |
0%
|
| 3-Year Average | 16.2 | €282.67 |
-8%
|
| 5-Year Average | 17.4 | €303.1 |
-1%
|
| Industry Average | 3.1 | €54.46 |
-82%
|
| Country Average | 2.5 | €43.85 |
-86%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Shockwave Medical Inc
F:36M
|
11.3B EUR | 17.6 | 81.1 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 9.6 | 60 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 3 | 25.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 5.6 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 2.2 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 3.8 | 25.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40B EUR | 2.2 | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 4.7 | 44.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 28.1 | 42.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 1.7 | 24.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 5.1 | 21.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
Shockwave Medical Inc
Glance View
Shockwave Medical Inc. has established itself as a significant player in the healthcare sector thanks to its innovative approach to tackling calcified cardiovascular disease. Founded with the vision of addressing the inefficiencies and limitations of traditional treatment methods, the company has embarked on a path that fuses medical expertise with cutting-edge technology. The core of Shockwave's operation lies in its proprietary intravascular lithotripsy (IVL) technology, which employs sonic pressure waves to safely and effectively fracture problematic calcium deposits in the arteries. This approach not only enhances the safety profile compared to other invasive procedures but also improves the outcomes for patients enduring complex calcified lesions, a common hurdle in cardiovascular treatments. It's through the pioneering use of this technology that Shockwave Medical generates its revenue. The company's product portfolio, which includes devices like the Shockwave M5 and Shockwave C2 catheters, is designed to cater to a wide spectrum of calcified cardiovascular issues. By selling these devices directly to hospitals and healthcare providers across the globe and supporting them with robust clinical data showing improved patient outcomes, Shockwave has cemented its place in the medical device industry. Furthermore, its business model benefits from recurring revenues as healthcare providers continually purchase these specialized devices for ongoing procedures. This consistent demand underscores the company's balanced approach to innovation and profitability in a market primed for technological advancements.